TAM
AKRO icon

Tiverton Asset Management’s Akero Therapeutics AKRO Stock Holding History

Tiverton Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$64K Hold
2,800
– – ﹤0.01% 680
2019
Q2 		$54K Buy
+2,800
New +$53.1K ﹤0.01% 663

Other funds holding AKRO

VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Tiverton Asset Management's AKRO Position: Q3 2019 in Review

Tiverton Asset Management held its Akero Therapeutics (AKRO) position steady in Q3 2019 at 2,800 shares worth $64K. The position accounts for ﹤0.01% of the portfolio, ranked #680.

Tiverton Asset Management first reported a position in AKRO in Q2 2019 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold AKRO as of Q3 2019.

  • Tiverton Asset Management held 2,800 shares of Akero Therapeutics worth $64K as of Q3 2019.
  • Tiverton Asset Management left its Akero Therapeutics share count unchanged in Q3 2019.
  • Akero Therapeutics made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #680 holding.
  • Tiverton Asset Management first reported a position in Akero Therapeutics in Q2 2019 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.